Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform
Creates a robust immunology pipeline with significant value-creating milestones, and provides a strong clinical and research team with complementary expertise in immuno-inflammatory diseases
Closing consideration of 5,699,492 shares of common stock of Equillium
Equillium to host a conference call and webcast today at 8:00 a.m. Eastern Time
Webcast and Conference Call
Management will host a conference call accompanied by a slide presentation to discuss the acquisition of Bioniz for analysts and institutional investors, at 8:00 am ET today, February 16, 2022. To access the call, please dial (888) 350-3846 or (646) 960-0251 and, if needed, provide confirmation number 8770084. A live webcast of the call will also be available on the company’s Investor Relations page at https://ir.equilliumbio.com/events-and-presentations. The webcast will be archived for 180 days.
https://finance.yahoo.com/news/equillium-acquires-bioniz-therapeutics-significantly-120000412.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.